HB 56 Allows pharmaceutical companies to rebate portions of copayments to multiple sclerosis patients without violating anti-kickback and anti-rebate laws
Sponsor: Dolan
LR Number: 0254L.04T Fiscal Note: 0254-04
Committee: Aging, Families, Mental & Public Health
Last Action: 7/14/2005 - Signed by Governor Journal Page:
Title: HCS HB 56 Calendar Position: 14
Effective Date: August 28, 2005
House Handler: Threlkeld

Full Bill Text | All Actions | Available Summaries | Senate Home Page | List of 2005 Senate Bills

Current Bill Summary


HCS/HB 56 - This act provides that the anti-kickback, anti-rebating and other prohibited financial incentive provisions of Section 191.905 shall not apply to pharmaceutical programs that rebate a portion of health insurance copayments and coinsurance to multiple sclerosis patients or others suffering from chronic conditions who have been prescribed medicines for which there are no generic equivalents.

STEPHEN WITTE